01—Abstract
Summary
Summary of the 10-Q filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation (EW) reported strong top-line growth in its second quarter and first six months of 2025, with net sales increasing by 11.9%a and 9.1% respectively compared to the prior year.
This growth was primarily driven by robust performance in Transcatheter Aortic Valve Replacement (TAVR) and a significant surge in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, up 61.9%b and 60.1% for the respective periods. The company also saw continued growth in its Surgical Structural Heart segment. While revenue growth was positive, gross profit margin experienced a slight decline due to higher manufacturing expenses for new therapies and foreign currency impacts.
The company also recorded a notable loss on impairment of $47.1 millionc related to an unexercised acquisition option. The balance sheet shows an increase in cash and cash equivalents and a decrease in accounts payable. Investors should monitor the company's ongoing litigation and tax matters, particularly the significant IRS transfer pricing dispute, which continues to present a potential financial risk.
02—Key points
Key Highlights
- Net sales increased by 11.9% to $1.53 billion for the three months ended June 30, 2025, and by 9.1% to $2.94 billion for the six months ended June 30, 2025, compared to the prior year.
- Transcatheter Mitral and Tricuspid Therapies (TMTT) sales saw substantial growth, increasing by 61.9% and 60.1% for the three-month and six-month periods respectively.
- Gross profit margin decreased slightly due to higher manufacturing expenses and foreign currency fluctuations.
- The company recorded a $47.1 million loss on impairment related to a decision not to exercise an option to acquire a medical device company.
- Cash and cash equivalents increased to $3.27 billion as of June 30, 2025, up from $3.05 billion at December 31, 2024.
- The company is actively managing a significant IRS transfer pricing dispute, with potential tax liabilities and ongoing legal proceedings.
- Edwards Lifesciences continues to execute its share repurchase program, with $1.1 billion remaining authorization as of June 30, 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Edwards Lifesciences kept $0.22.
- Revenue$1.53B100.0%
- Cost of revenue−$344.4M22.5%
- Gross profit$1.19B77.5%
- Operating costs−$776.6M50.7%
- Operating income$411.2M26.8%
- Interest, other & tax−$79.7M5.2%
- Net income$331.5M21.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 6, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $1.53B$1.37B | +11.9% |
| Cost of Revenue | $344.40M$275.50M | +25.0% |
| Gross Profit | $1.19B$1.09B | +8.6% |
| R&D Expenses | $276.20M$271.80M | +1.6% |
| SG&A Expenses | $502.00M$447.50M | +12.2% |
| Operating Income | $411.20M$366.50M | +12.2% |
| Net Income | $331.50M$365.00M | −9.2% |
| EPS (Basic) | $0.57$0.61 | −6.6% |
| EPS (Diluted) | $0.56$0.61 | −8.2% |
| Shares Outstanding (Basic) | 587.00M602.10M | −2.5% |
| Shares Outstanding (Diluted) | 587.90M604.30M | −2.7% |
05—Questions
Frequently Asked Questions
What drove the revenue growth in the reported periods?
Revenue growth was primarily driven by strong sales performance in the Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product categories. The TMTT segment, in particular, showed significant acceleration.
What is the impact of the sale of the Critical Care product group?
The Critical Care product group, sold in September 2024, and a non-core product group to be sold in 2025, are now reflected as discontinued operations in the financial statements. This simplifies the company's focus on its core structural heart disease business.
What is the nature of the significant tax-related matters the company is facing?
The company is involved in a substantial IRS transfer pricing dispute concerning royalty transactions for tax years 2015-2017, with a potential tax liability of $269.3 million plus interest. Similar disputes may arise for later tax years. The company also faces ongoing proceedings with the Israel Tax Authority. While the company believes its current accruals are appropriate, these matters represent a material uncertainty and potential financial risk.
How is the company managing its capital and liquidity?
Edwards Lifesciences maintains a strong liquidity position with $3.27 billion in cash and cash equivalents as of June 30, 2025. The company also has an undrawn $750 million revolving credit facility. It continues to execute its share repurchase program, indicating confidence in its financial health and ability to return capital to shareholders.
06—Continue